Overview

Clinical Trial to Assess Effect of Verapamil on Systemic Exposure of EP395 and Effect of EP395 on Systemic Exposure of Midazolam and Digoxin

Status:
Completed
Trial end date:
2024-01-02
Target enrollment:
Participant gender:
Summary
The aim of this trial is to assess the potential key drug-drug interactions with EP395 in the clinical setting.
Phase:
Phase 1
Details
Lead Sponsor:
EpiEndo Pharmaceuticals
Collaborator:
CTC Clinical Trial Consultants AB
Treatments:
Digoxin
Midazolam
Verapamil